目的 盾叶冠心宁片与复方丹参滴丸治疗冠心病稳定型心绞痛临床疗效比较。方法 选取于2017年10月—2018年10月至延安大学附属医院诊治的120例冠心病稳定型心绞痛患者。随机将所有患者分为2组,观察组患者在常规西药治疗基础上加服盾叶冠心宁片,对照组患者在常规西药治疗基础上加服复方丹参滴丸,比较两组患者治疗6个月后的临床疗效。结果 经过6个月治疗后,观察组患者的治疗有效率为66.7%,对照组患者的治疗有效率为40.0%。观察组与对照组治疗效果相比,差异有统计学意义(P＜0.05)。盾叶冠心宁片治疗冠心病稳定型心绞痛的综合疗效优于复方丹参滴丸。结论 冠心病稳定型心绞痛患者在常规西药治疗不变的基础上加用盾叶冠心宁片,不仅能改善临床心绞痛症状,还能调节血脂异常及降低同型半胱氨酸水平,以及缓解患者情绪及睡眠问题,且安全性高,有较高临床应用价值。

Objective To compare the clinical efficacy of Dunye Guanxinning tablets and Compound Danshen dropping pills in the treatment of stable angina pectoris caused by coronary heart disease. Methods 120 patients with stable angina pectoris were selected from the affiliated hospital of Yan'an University from October 2017 to October 2018.All patients were randomly divided into two groups. The observation group was treated with Dunye Guanxinning tablets on the basis of conventional western medicine, while the control group was treated with Compound Danshen dropping pills on the basis of conventional western medicine. The clinical efficacy of the two groups was compared after 6 months of treatment. Results After 6 months of treatment, the effective rate was 66.7% in the observation group and 40.0% in the control group. The treatment effect of the observation group was statistical different from that of the control group (P<0.05). The comprehensive curative effect of Dunye Guanxinning tablets in treating stable angina pectoris of coronary heart disease is better than that of Compound Danshen dropping pills. Conclusion The use of Dunye Guanxinning tablets in patients with stable angina pectoris after conventional western medicine treatment may not only improve the symptoms of clinical angina pectoris, but also regulate dyslipidemia and reduce homocysteine level, as well as alleviate the patients' emotional and sleep problems. It has high safety and high clinical application value.

目的 探讨鼻内镜鼻前庭囊肿揭盖术治疗鼻前庭囊肿的临床疗效。方法 选择2014年8月-2017年8月我院收治的60例鼻前庭囊肿患者为研究对象,根据手术方式不同分为两组,每组各30例。对照组采用传统唇龈沟径路鼻前庭囊肿切除术进行治疗,观察组采用鼻内镜鼻前庭囊肿揭盖术治疗;评价两组手术情况、术后疼痛程度及并发症发生情况,术后随访1年,观察两组患者的复发情况。结果 对照组手术时间、术中出血量、术后住院时间分别为（44.78±8.13）min、（37.09±7.11）mL、（7.27±1.45）d均高于观察组的（17.91±4.26）min、（8.85±3.12）mL、（5.02±1.06）d,差异有统计学意义（P<0.05）;对照组术后24 h、48 h、72 h的VAS评分分别为（3.53±1.07）分、（2.84±1.12）分、（2.34±0.69）分均高于观察组的（2.92±1.14）分、（2.21±1.00）分、（1.73±0.76）分,差异有统计学意义（P<0.05）;对照组术后并发症发生率为26.67%,复发率为20.00%,高于观察组的6.67%、0.00%,差异有统计学意义（P<0.05）。结论 鼻内镜鼻前庭囊肿揭盖术治疗鼻前庭囊肿疗效显著,具有手术时间短、出血量少的优点,可减轻患者术后疼痛,减少术后并发症的发生,利于加速患者恢复,预后较好。

Objective To investigate the clinical efficacy of nasal endoscopic nasal vestibular cyst uncovering for nasal vestibular cyst. Methods Sixty patients with nasal vestibular cysts admitted to our hospital from August 2014 to August 2017 were enrolled in the study. They were divided into two groups according to different surgical methods,30 in each group. The control group was treated with traditional sacral sulcus cystectomy. The observation group was treated with nasal endoscopic nasal vestibular cyst uncovering for nasal vestibular cyst. The operation status,postoperative pain degree and complications were evaluated. After one year,the recurrence of the two groups of patients was observed. Results The operation time,intraoperative blood loss and postoperative hospital stay were （44.78±8.13） min,（37.09±7.11） mL,and （7.27±1.45）d,respectively,which were higher than the observation group （17.91±4.26） min. （8.85±3.12） mL,（5.02±1.06） d,the differences were statistically significant （P<0.05）;the VAS scores of the control group at 24h,48h,72h were （3.53±1.07） points,（2.84±1.12）. The scores of （2.34±0.69） were higher than those of the observation group （2.92±1.14）,（2.21±1.00）,and （1.73±0.76）,the differences were statistically significant （P<0.05）. The postoperative complication rate was 26.67%,and the recurrence rate was 20.00%,which was higher than that of the observation group （6.67%,0.00%）. The differences were statistically significant （P<0.05）. Conclusion Endoscopic nasal vestibular cyst is a significant treatment for nasal vestibular cyst. It has the advantages of short operation time and less bleeding. It may reduce postoperative pain,reduce postoperative complications,and accelerate the recovery of patients. It is good at prognosis.

目的 总结GuideLiner^®延长导管在复杂经皮冠状动脉介入治疗(PCI)中的初步经验,探讨其有效性及安全性。方法 选择2015年3月—2017年3月因冠心病于广州市第一人民医院行PCI的患者13例,因复杂病变需要更强支撑力而使用GuideLiner^®延长导管完成手术,总结手术成功率、并发症以及6个月随访主要不良心脏事件的发生情况。结果 13例患者在GuideLiner^®延长导管应用下均成功完成手术。使用延长导管的目的2例手术为辅助球囊通过,7例为辅助支架通过,4例为辅助支架及球囊通过。全部患者均未发生术中及住院期间死亡、急性心肌梗死,未发生急性支架内血栓形成、目标冠脉夹层或穿孔、心包填塞等并发症,6 个月随访均无不良心脏事件发生。结论 应用延长导管可提高支撑力,有效辅助球囊和/或支架到达冠状动脉病变部位,提高手术成功率,安全性较高。

Objective To evaluate the clinical efficacy and safety of GuideLiner^® guide extension catheter during complex coronary percutaneous coronary intervention(PCI) procedures. Methods Thirteen patients with coronary heart diseases performed PCI procedures were included in this study from March 2015 to March 2017. GuideLiner^® guide extension catheters were used in these complex cases. The PCI success rate,incidence of complications and 6-month follow up data were observed. Results Benefited from the stronger support produced by GuideLiner^®, PCI success rate was 100%. The guide extension catheters were used for the delivery of balloons in 2 cases, while 7 cases for stents, and 4 cases for both balloons and stents. No death were observed during the procedure or in hospital, and there were no dissection or acute myocardial infarction. During 6 months of follow-up,there was no major adverse cardiac events (MACE). Conclusion GuideLiner^® guide extension catheter may improve procedure success rate by ensuring the delivery of balloons and stents in complex PCI.

目的 探讨复合声及心理辅导联合耳后注射利多卡因与甲强龙综合治疗特发性耳鸣的临床疗效。方法 选择符合纳入标准的耳鸣患者60例,随机分为耳后注射利多卡因与甲强龙组(A组)20例、心理辅导联合复合声组(B组)20例、耳后注射利多卡因与甲强龙联合心理辅导及复合声组(C组)20例,分别于治疗后1月、3月,通过耳鸣严重程度评估指标及评分标准评估三种治疗方式的疗效。结果 3组患者治疗3个月后A组总有效率为50 %, B组45%, C组90%,且组间有差异(P＜0.05)。另外,除A组与B组之间无差异外,C组与A组(P=0.0058)、B组(P=0.0024)之间均有差异。结论 实验结果表明复合声及心理辅导联合利多卡因与甲强龙综合治疗特发性耳鸣能有效治疗耳鸣,提高患者生存质量,在耳鸣临床治疗中明显具有积极作用,临床应用前景广阔。

目的 探讨高血压性脑出血在不同时点给药丹参酮ⅡA磺酸钠的疗效分析及对神经保护作用。方法 选取我院2014年10月—2016年10月期间收治的66例高血压性脑出血患者作为研究对象,按照随机数字表的方法分为观察组(n=33)和对照组(n=33),对照组患者于入院后第10天采用丹参酮ⅡA磺酸钠进行治疗,观察组则于入院后第3天采用丹参酮ⅡA磺酸钠进行治疗,分别对2组患者的临床疗效、不良反应、治疗前后的神经功能以及随访一年的脑卒中影响量表(SIS)进行客观比较。结果 经比较,观察组患者的临床总有效率为90.90%,对照组的临床总有效率为69.70%,2组比较,差异有统计学意义(P<0.05);观察组患者的不良反应稍低于对照组,但2组比较差异无统计学意义(P>0.05);此外,观察组患者治疗后的神经功能评分优于对照组和治疗前,差异有统计学意义(P<0.05);在随访一年的时间里发现,观察组患者的SIS量表亦更优于对照组(P<0.05)。结论 早期采用药丹参酮ⅡA磺酸钠治疗高血压性脑出血的临床疗效显著,不良反应相对较小,且在一定程度上发挥了保护患者神经功能的作用,值得推广。

Objective: To investigate the effect of tanshinone II A sulfonate treatment on hypertensive cerebral hemorrhage at different time and the neuroprotective effect. Methods: In our hospital from October 2014 to October 2016 66 cases of hypertensive cerebral hemorrhage patients were enrolled as the research object, according to the random number table method divided into observation group (n=33) and control group (n=33), patients in the control group on the tenth day after admission of sodium tanshinone A sulfonate treatment, The observation group was treated with tanshinone A sodium sulfonate on the third day after admission. The clinical efficacy, adverse reactions, neurological function before and after treatment, and Stroke Scale (SIS) were compared between the two groups. Results: by comparison, the observation group of patients with clinical total efficiency 90.90%, clinical control group in the total efficiency 69.70%, compared with significant difference (P<0.05); to observe the adverse reaction of patients was slightly lower than that of control group, but the difference between the two groups was not statistically significant (P>0.05); in addition, the patients in the observation group the neurological score was significantly better than the control group and before treatment, the difference was significant (P<0.05); Conclusion: the early treatment of sodium tanshinone II A sulfonate in the treatment of hypertensive intracerebral hemorrhage has a significant clinical effect, a relatively small adverse reaction, and to a certain extent, it plays a protective role in patients with neurological function, and is worthy of promotion.

目的 探讨双柏散与喜疗妥软膏治疗经外周静脉穿刺置入中心静脉导管(PICC)相关性静脉炎的临床疗效对比。方法 选取PICC相关性静脉炎患者80例,随机分为观察组和对照组各40例,观察组采用双柏散水蜜制剂外敷,对照组采用喜疗妥软膏外涂,观察2组临床疗效。结果 观察组显效率87.5％,总有效率97.5％;对照组显效率65％,总有效率80％。观察组显效率和总有效率均高于对照组(P<0.05)。两组在治疗后各时点疼痛评分均低于治疗前(P<0.01);对照组在治疗24h后各治疗时点疼痛评分均低于治疗前,差异有显著性意义(P<0.01),但在12 h治疗时点疼痛评分虽亦低于治疗前,但差异无显著性意义(P>0.05)。观察组患者在治疗后12 h、24 h、36 h和48 h时点的静脉炎疼痛评分均低于对照组,差异有显著性意义(P<0.01或P<0.05),而在72 h时点两组疼痛评分差异无显著性意义(P>0.05)。结论 本研究结果表明双柏散外敷治疗PICC相关性静脉炎效果优于喜疗妥组,且疼痛症状改善时间更早。

Objective To compare clinical efficacy in the treatment of phlebitis correlation with peripherally inserted central catheter (PICC) between Shuangbai Powder and Hirudoid cream. Methods 80 patients with PICC correlation phlebitis were randomly divided into observation group and control group. There were 40 cases in the observation group treated with Shuangbai Powder and 40 cases in the control group treated with Hirudoid cream. We observed clinical curative effect of two groups. Results The efficiency rate was 87.5% and total effective rate was 97.5% in the observation group. The efficiency rate was 65% and total effective rate was 80% in the control group. The difference of the efficiency rate and total effective rate between observation group and control group was significance (P<0.05). The pain scores were lower in observation group after treatment than it was before(P<0.01);The pain scores were lower in control group after 24 hours treatment than it was before(P<0.01);The pain scores after 12 hours of treatment lower than before, but there was no significant difference(P>0.05). The pain scores after 12 hours,24 hours,36 hours and 48 hours of treatment in observation group were lower than control group(P<0.01 or P<0.05),but there was no significant difference in the pain score of both groups after 72 hours of treatment(P>0.05). Conclusion The clinical efficacy in the treatment of phlebitis correlation with peripherally inserted central catheter (PICC) by Shuangbai Powder is better than Hirudoid cream, and the time of pain relief in the group treated by Shuangbai Power is earlier than it treated by Hirudoid cream.

目的 观察甲氨蝶呤(MTX)联合激素、羟氯喹治疗轻、中度活动性系统性红斑狼疮(SLE)的实验室结果分析及临床应用价值。方法 选择我院收治的系统性红斑狼疮患者60例,随机分成研究组(n=30)与对照组(n=30),对照组给予糖皮质激素0.5～1.0 mg/(kg·d)及羟氯喹治疗,研究组给予口服MTX片剂每周一次7.5～15 mg联合糖皮质激素及羟氯喹(用法同对照组),比较分析两组患者的实验室检查结果差异。结果 与治疗前相比,研究组患者的ANA、抗ds-DNA滴度及ESR、CRP的下降都明显优于对照组(P＜0.05);研究组患者的ALT、AST、BUN、SCr及血象(WBC、Hb、PLT)指标也明显优于对照组(P＜0.05);研究组患者补体(C3、C4) 也明显高于对照组(P＜0.05)。结论 加用MTX治疗SLE有效,安全性良好,且联合治疗能更好地控制疾病,减少复发,防止及延缓重要脏器的损害。缓解患者的临床症状,为SLE患者提供一个安全、有效的治疗方案。

目的 探讨分析氨茶碱治疗早产儿呼吸暂停的临床疗效及其在治疗过程中所出现的不良事件。方法 选取2014年9—2016年3月广州市第一人民医院新生儿科接受住院治疗的胎龄＜34周,生后2 h内入住新生儿科的早产儿42例。随机分为对照组和氨茶碱组,对照组(20例)给予保暖、吸氧、补充能量、保持呼吸道通畅、物理刺激等对症治疗,不使用氨茶碱及其它改善呼吸的药物;氨茶碱组(22例)患儿除给予对照组治疗措施外,同时给予氨茶碱静脉滴注,首剂负荷量5 mg/kg,在20min内完成,12 h后以2～2.5 mg/kg维持量,每隔12 h一次。观察两组的疗效与不良影响。结果 ①两组患儿性别、出生胎龄、出生体重、产前孕母糖皮质激素的应用、受孕方式、分娩方式、多胎妊娠、5min Apgar评分、机械通气及CPAP辅助通气例数、低-中流量吸氧(箱内或头罩给氧)例数等方面差异均无统计学意义(P均＞0.05)。②与对照组相比,氨茶碱组早产儿呼吸暂停(AOP)发生的次数较少,AOP消失所需时间较短,差异均有统计学意义(P＜0.05)。③不良影响方面,氨茶碱组脑白质发育不良发生率(63.6%,14/22例)显著高于对照组(25%,5/20例),差异有统计学意义(P＜0.05);两组患儿在听力检查异常、喂养不耐受、血糖紊乱、血脂代谢紊乱、血红蛋白下降、电解质紊乱、出院时体重及住院时间等方面均无统计学意义(P均＞0.05)。④氨茶碱组视网膜发育不完全的发生率(40.9%,9/22例)明显高于对照组(15.0%,3/20例),但差异无统计学意义(P＞0.05)。结论 小剂量氨茶碱在防治AOP方面的作用是值得肯定的,但它有可能增加早产儿脑白质发育不良的风险与视网膜发育不完全的风险。

Objective To investigate the clinical efficacy and adverse effects of aminophylline in prevention of apnea of prematurity. Methods Forty-two infants with gestational age ＜34 weeks admitted to department of pediatrics, Guangzhou first people's hospital between Sep. 2014 and Mar. 2016 were randomly divided into 2 groups: control group and aminophylline group. Control group(n=20): 20 infants received warming, oxygen inhalation, supplement energy, maintain airway patency, physical stimulation, such as symptomatic treatment, without aminophylline or any other drugs for improving breathing. Aminophylline group(n=22): In addition to the control group treatment measures, 22 infants received a loading dose of 5 mg/kg of aminophylline and then maintained by a dose of 2mg/kg with intravenous drip q 12 h. Then we compared the efficacy and adverse effects of the two groups. Results ①There was no significant difference in gender, gestational age, birth weight, maternal antenatal glucocorticoid application, pregnancy(including multiple pregnancy) and delivery,5 min Apgar score, oxygen therapy, the application of mechanical ventilation, nasal continuous positive airway pressure, and the low-medium flow oxygen inhalation between the 2 groups(all P＞0.05). ② Compared with the control group, the incidence of apnea in aminophylline group were significant lower, and the time needed for apnea to disappear were significant shorter(all P＞0.05). ③ The incidence of cerebral white matter development dysplasia of aminophylline group(63.6%,14/22 cases) were significant higher than the control group(25%,5/20 cases, P＜0.05). There was no statistically significant difference in hearing loss, feeding intolerance, blood glucose disturbance, blood lipid metabolism disorder, hemoglobin decrease, electrolyte disorder, body weight at discharge, the duration and cost of hospitalization between the 2 groups(all P＞0.05). ④ The incidence of retinal incompleted development of aminophylline group(40.9%, 9/22 cases) were higher than control group(15.0%, 3/20 cases), but there was no statistical significance between the 2 groups(P＞0.05). Conclusion Effects of aminophylline in treating apnea of prematurity is positive, but it is likely to increase the risk of premature brain white matter development dysplasia and the risk of retinal incompleted development.

目的 观察氟伐他汀联合环磷腺苷葡胺治疗慢性肺心病急性加重期的临床疗效。方法 将我院收治的74例慢性肺心病急性加重期病人,使用随机数字表法分为联合用药组与对照组,每组各37例。对照组单独使用环磷腺苷葡胺,联合用药组在对照组的基础上加服氟伐他汀。两组疗程均为7周。观察比较两组患者治疗前后的NO,ET-1,CRP,PaO₂水平以及治疗效果。结果 经7周疗程治疗后,对照组有效率为64.86%,联合用药组94.59%。两组间比较,差异有统计学意义(P<0.05)。两组NO,ET-1,CRP,PaO₂水平比较,联合用药组均优于对照组,差异有统计学意义(P<0.05)。结论 氟伐他汀联合环磷腺苷葡胺治疗慢性肺心病急性加重期的临床疗效更为显著,值得临床推广。

Objective To observe the clinical efficacy of combined treatment of Fluvastatin combined with Meglumine Adenosine Cyclophosphate on acute exacerbation of chronic pulmonary heart disease. Methods 74 patients with acute exacerbation of chronic pulmonary heart disease were randomly divided into combined treatment group and control group. The control group was treated by Meglumine Adenosine Cyclophosphate for 7 weeks.The combined treatment group was treated by Meglumine Adenosine Cyclophosphate and Fluvastatin for 7 weeks. The clinical efficacy and the score of NO,CRP,ET-1,PaO₂ were assessed before and after the treatment. Results After 7 weeks treatment, the total clinical efficacy rate was 64.86% in the control group and 94.59% in the combined treatment group. The differences between them has statistically significant(P<0.05). The score of NO,ET-1,CRP,PaO₂ in combined treatment group were significantly improved compared to control group (P<0.05). Conclusion The clinical efficacy of Fluvastatin combined with Meglumine Adenosine Cyclophosphate on acute exacerbation of chronic pulmonary heart disease is more efficient. It is worth to develop clinically.

目的 探讨内镜下逆行胰胆管造影( ERCP) 治疗胆总管结石患者的临床疗效及其相关并发症。方法 严格筛选纳入从2012年1月—2015年1月在我院行ERCP治疗的胆总管结石患者,归纳评估ERCP手术对胆总管结石治疗的有效性及安全性。结果 359例胆总管结石患者,其中行ERCP治疗共347例,其中9例因一般情况差无法耐受手术或无法配合而未予以实施ERCP治疗,其中3例因术中穿孔转为开放手术治疗。 1次性取净结石者311例(89.6%),结石2次以上(含2次)取净者27例(7.8%),放置胆道支架者9 例(2.6%)。ERCP 术后总胆红素(61.7±103.8) μmol/L; 直接胆红素(34.7±59.6) μmol/L; 谷丙转氨酶(62.8±74.2) U/L; 谷草转氨酶(48.3±61) U/L。术后 2 h血淀粉酶(115±162) U/L,无统计学差异(P＞0.05) ,24 h血淀粉酶(124.7±215.8)U/L,与术前相比差异有统计学意义(P＜0.05) 。术后寒战、发热、腹痛、黄疸等症状均有不同程度的减轻;肝功能术后明显好转(P＜ 0.05);术后平均住院天数4～6 d;出现并发症患者16例,其中急性胰腺炎占6例,急性胆管炎占5例,出血占3例,穿孔占2例,经对症支持治疗后均治愈出院。结论 ERCP 治疗胆总管结石安全、有效,临床疗效显著,是胆胰疾病重要的诊治手段。

Objective To investigate the clinical efficacy and complications of endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of common bile duct stones. Methods Cases received ERCP therapy from January 2012 to January 2015 were studied retrospectively,and evaluated the safety and efficacy of therapeutic ERCP in patients with common bile duct calculi. Results 359 Cases of patients with common bile duct stones treated successfully with 347 cases,among them 9 cases unable to implementation of ERCP because of bad surgery tolerance,3 cases of intraoperative perforation to have surgical operation treatment. The stones were removed completely one time in 311 cases(89.6%). More than two times removing net calculi in 27 cases(7.8%). 9 cases were placed biliary stent (2.6%). Postoperative total bilirubin ERCP:61.7 ±103.8 μmol / l; Postoperative bilirubin direct: 34.7±59.6 μmol/l; Postoperative ALT:62.8±74.2 U/L; Postoperative AST: 48.3±61 U/L; Postoperative 2 h blood amylase was 115±162 U/L. It showed no significant difference (P＞0.05).24 h blood amylase was 124.7±215.8 U/L,there was significant difference compared with before operation(P＜0.05). Postoperative chills,fever, pain,jaundice have different degrees of ease. Postoperative liver function was improved significantly(P＜0.05). The postoperative average length of stay in common bile duct stones was 4～ 6 days. Complications occurred in 16 cases,including 6 cases of acute pancreatitis,5 cases of acute cholangitis,3 cases of bleeding,perforation in 2 cases. After treatment they were cured and discharged. Conclusion ERCP is safe,effective in treatment of common bile duct stones. It is an important means in treatment in bile duct diseases